Interview with Jean-Francois H. Geschwind.

Interview with Yujin Hoshida.

Interview with K. Rajender Reddy.

Interview with Mark W. Russo.

Interview with Lewis R. Roberts.

Both nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN) have proven to be effective, but current guidelines are lacking clear recommendations as to which treatment strategy should be used as first-line therapy. The authors review the best available evidence regarding which patients should be treated with interferon

: HBV is noncytopathic, with hepatic injury occurring as a result of the host immune response against the virus. As a result, the interaction between HBV and the immune system is critical in determining the outcome of infection. Dr. Feld reviews reverse seroconversion, HBV reactivation, prevention, screening, and management strategies.

All newly diagnosed chronic Hepatitis B patients should undergo a complete history, physical assessment, and laboratory assessment in an effort to assess the severity of liver disease and potential need for antiviral therapy. Watch, read, or listen to Dr. Fontana describe recommended testing and markers of HBV replication, as well as other approaches to evaluating the patient..

This liver biopsy from a patient with markedly active chronic hepatitis B has considerable chronic portal inflammation, predominantly lymphocytes, which migrate out of the portal tract to surround and destroy adjacent hepatocytes. Review this and other histologic features associated with the active immune response to HBV in Dr. Goodman’s review of hepatopathology of HBV.

Most cases of Hepatitis B that cause long-term morbidity and mortality had their origin during the patient’s childhood, according to Maureen Jonas, MD from Boston Children’s Hospital and Harvard Medical School. Listen to the podcast to better understand the risks of and management strategies for HBV in children, and to review monitoring and treatment algorithms for children with HBV.